Bristol Myers Squibb (BMS) will invest $2.3 billion to build a new manufacturing campus in Houston, Texas. The multi-modal facility will produce both small molecules and biologics. This site supports the company's drug pipeline from late-stage development through commercial launch.
The project is part of a broader $40 billion five-year commitment to U.S. research and manufacturing. The Houston campus will create nearly 500 skilled jobs. A modular design allows for future expansion and reconfiguration as the drug pipeline evolves.
BMS aims to accelerate the delivery of next-generation medicines by strengthening internal manufacturing. The facility provides flexibility to produce a diverse range of therapies. This infrastructure ensures the company can adapt to future technological advances in drug development.